Literature DB >> 19305108

A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma.

Nobuaki Kobayashi1, Noritake Hata, Shinya Yokoyama, Takuro Shinada, Akihiro Shirakabe, Kyoichi Mizuno.   

Abstract

A case of acute heart failure due to Takotsubo cardiomyopathy induced by 5-fluorouracil is described. Acute heart failure developed during the administration of 5-fluorouracil (5-FU) and levofolinate calcium in a 62-year-old woman who had underwent a Miles operation for rectal adenocarcinoma. Electrocardiography upon admission showed slight ST elevation in leads V1-3, and follow-up electrocardiography on the third hospital day evealed QT interval prolongation and giant negative T waves in leads II, III, aVF, and V1-6. Echocardiography and myocardial scintigraphy showed left ventricular apical ballooning in the acute phase of heart failure, but left ventricular contraction was normal during the recovery phase. Coronary angiography demonstrated normal coronary arteries, and multi-vessel coronary artery vasospasms including microcirculation disorders could be provoked by intracoronary acetylcholine infusion during, but not before, the intravenous administration of levofolinate calcium and 5-FU. The cause of heart failure in this patient, Takotsubo cardiomyopathy induced by multivessel coronary vasospasm including microcirculation disorders only during 5-FU administration, is notable.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19305108     DOI: 10.1272/jnms.76.27

Source DB:  PubMed          Journal:  J Nippon Med Sch        ISSN: 1345-4676            Impact factor:   0.920


  12 in total

1.  Initial clinical presentation of Takotsubo cardiomyopathy with-a focus on electrocardiographic changes: A literature review of cases.

Authors:  Erick Francisco Sanchez-Jimenez
Journal:  World J Cardiol       Date:  2013-07-26

Review 2.  Arterial events in cancer patients-the case of acute coronary thrombosis.

Authors:  Ohad Oren; Joerg Herrmann
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 3.  Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

Authors:  Joerg Herrmann; Eric H Yang; Cezar A Iliescu; Mehmet Cilingiroglu; Konstantinos Charitakis; Abdul Hakeem; Konstantinos Toutouzas; Massoud A Leesar; Cindy L Grines; Konstantinos Marmagkiolis
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

4.  5-Fluorouracil-induced acute reversible heart failure not explained by coronary spasms, myocarditis or takotsubo: lessons from MRI.

Authors:  Yama Fakhri; Morten Dalsgaard; Dorte Nielsen; Per Lav Madsen
Journal:  BMJ Case Rep       Date:  2016-06-01

Review 5.  Common Vascular Toxicities of Cancer Therapies.

Authors:  Joerg Herrmann
Journal:  Cardiol Clin       Date:  2019-08-26       Impact factor: 2.213

6.  Takotsubo cardiomyopathy caused by infusion reaction to trastuzumab.

Authors:  Toshihiko Matsumoto; Takashi Oda; Yu Yoshida; Shogo Kimura; Hitomi Himei; Takao Tsuduki; Shinjiro Takagi; Masahiro Takatani; Hirofumi Morishita
Journal:  Int Cancer Conf J       Date:  2019-12-06

7.  Hemodynamic support with TandemHeart in tako-tsubo cardiomyopathy - a case report.

Authors:  Babak Hassid; Shah Azmoon; Wilbert S Aronow; Chandrasekar Palaniswamy; Martin Cohen; Alan Gass
Journal:  Arch Med Sci       Date:  2010-12-29       Impact factor: 3.318

Review 8.  Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-30       Impact factor: 32.419

9.  Takotsubo cardiomyopathy and 5-Fluorouracil: getting to the heart of the matter.

Authors:  Stephanie Hui-Su Lim; Sharon Mary Wilson; Arnagretta Hunter; Jane Hill; Philip Beale
Journal:  Case Rep Oncol Med       Date:  2013-12-03

10.  Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients' heart?

Authors:  Caterina Fontanella; Marianna Aita; Marika Cinausero; Giuseppe Aprile; Maria Grazia Baldin; Veronica Dusi; Chiara Lestuzzi; Gianpiero Fasola; Fabio Puglisi
Journal:  Onco Targets Ther       Date:  2014-09-29       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.